Table 7.

The aPLs’ correlations in secondary APS.

	aCL IgG	aCL IgM	aβ2GPI IgG	aβ2GPI IgM	aPE IgG	aPE IgM	aPS IgG	aPS IgM	aPT IgG	aPT IgM
aCL IgG	1	0.37 *	0.46 **	0.52 **	0.29	0.43 **	0.68 **	0.46 **	0.34 *	0.27
aCL IgM	0.37 *	1	0.26	0.78 **	0.35 *	0.74 **	0.31 *	0.75 **	0.48 **	0.61 **
aβ2GPI IgG	0.46 **	0.26	1	0.46 **	0.30 *	0.38 *	0.29	0.56 **	0.25	0.29
aβ2GPI IgM	0.52 **	0.78 **	0.46 **	1	0.54 **	0.67 **	0.35 *	0.68 **	0.61 **	0.54 **
aPE IgG	0.29	0.35 *	0.30 *	0.54 **	1	0.53 **	0.47 **	0.42 **	0.58 **	0.18
aPE IgM	0.43 **	0.74 **	0.38 *	0.67 **	0.53 **	1	0.43 **	0.79 **	0.38 *	0.46 **
aPS IgG	0.68 **	0.31 *	0.29	0.35 *	0.47 **	0.43 **	1	0.42 **	0.26	0.14
aPS IgM	0.46 **	0.75 **	0.56 **	0.68 **	0.42 **	0.79 **	0.42 **	1	0.34 *	0.52 **
aPT IgG	0.34 *	0.48 **	0.25	0.61 **	0.58 **	0.38 *	0.26	0.34 *	1	0.28
aPT IgM	0.27	0.61 **	0.29	0.54 **	0.18	0.46 **	0.14	0.52 **	0.28	1

APS—antiphospholipid syndrome; aPLs—antiphospholipid antibodies; aCL—anti-cardiolipin antibodies; aβ2GPI—anti-β2 glycoprotein I antibodies; aPE—anti-phosphatidylethanolamine antibodies; aPS—anti-phosphatidylserine antibodies; aPT—anti-prothrombin antibodies; Ig—immunoglobulin; * p < 0.05; ** p < 0.01.